UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 2, 2014
Date of Report (Date of Earliest Event Reported)

IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

Delaware 000-31187 870299034
(State or other jurisdiction of (Commission File (IRS Employer Identification
incorporation) Number) No.)

6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[  ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))


Item 5.02. Appointment of Certain Officers.

IntelGenx today announced that its Board of Directors has unanimously appointed Dr. Horst G. Zerbe to serve as the Company’s President and Chief Executive Officer. Dr. Zerbe has served as interim President and CEO since July 15, 2014.

Dr. Zerbe (67) has more than 30 years’ experience in the pharmaceutical industry. Dr. Zerbe is the Chairman of the Board of Directors, Founder of IntelGenx, and former President and Chief Executive Officer of the Company. He retired from the positions of President and Chief Executive Officer effective December 31, 2013, a position that he held since April 2006. In addition, Dr. Zerbe served as the President, Chief Executive Officer and Director of IntelGenx Corp., our Canadian Subsidiary, from 2005 until December 31, 2013. From 1998 to 2005, he served as the President of Smartrix Technologies Inc. in Montreal; prior thereto, from 1994 to 1998, he was Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe has extensive executive level experience, and has been responsible for many strategic and business initiatives. Dr. Zerbe has been involved in new drug development and the acquisition and disposition of new drug candidates and other technology, licensing and distribution matters that are likely to affect our company’s own business efforts. He has published numerous scientific papers in recognized journals and holds over 30 patents. Dr. Zerbe is married to Ingrid Zerbe, the Company’s Corporate Secretary.

Item 8.01 Other Events.

On October 2, 2014, the Company issued a press release announcing the appointment of Dr. Horst G. Zerbe as President and Chief Executive Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit Description
99.1 Press Release dated October 2, 2014


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  INTELGENX TECHNOLOGIES CORP.
   
Dated: October 2, 2014 By: /s/ J. Bernard Boudreau
  J. Bernard Boudreau
  Vice Chairman of the Board of Directors





Exhibit 99.1

IntelGenx Founder Returns as President and CEO

Saint Laurent, Quebec - October 2, 2014 - Saint Laurent, Quebec - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its board of directors unanimously decided to appoint the company’s founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in the same roles from April 2006 to December 2013 and also has been serving as interim President and CEO since July 2014.

“As both a pioneer and expert in drug delivery systems, there is no better decision we could have made than to have Dr. Zerbe return to the helm of IntelGenx, said J. Bernard Boudreau, IntelGenx’ Vice-Chairman of the Board. “We are confident in his ability to move the company forward and create shareholder value.”

Dr. Zerbe has more than 30 years’ experience in Pharmaceutical R&D, technology management, business development and corporate management.

“During my entire professional carrier, and particularly since founding IntelGenx in 2003, it has been my goal to develop novel drug delivery systems that are of significant benefit to patients,” said Zerbe. “Although I have remained an integral part of company strategy and operations since its inception, I now look forward to once again leading IntelGenx as we bring our proprietary technologies into new markets and move the company towards revenue growth and profitability.”

Prior to founding IntelGenx, Dr. Zerbe served as the president of Smartrix Technologies Inc. in Montreal, and as Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe holds more than 40 patents in drug delivery related fields and has published numerous scientific papers in recognized journals.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.

Investor Contact: Company Contact:
   
COCKRELL GROUP Paul A. Simmons
T: 877.889.1972 Chief Financial Officer
investorrelations@thecockrellgroup.com IntelGenx Technologies Corp.
cockrellgroup.com T: +1 514-331-7440
  F: +1 514-331-0436
  intelgenx.com


IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more IntelGenx Technologies (QB) Charts.
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more IntelGenx Technologies (QB) Charts.